论文部分内容阅读
目的观察二甲双胍格列吡嗪复方制剂(A组)及单药二甲双胍(B组)或格列吡嗪(C组)治疗对T2DM患者血清内脏脂肪素(VF)水平及胰岛β细胞功能的影响。方法测定治疗前后FPG、FIns、2hPG、2hIns、HbA1c、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)、VF等相关指标。结果治疗后A、C组血清VF水平较治疗前下降(P<0.01),A组HOMA-β增加(P<0.01);Pearson相关性分析显示,治疗后VF水平与FPG、2hPG及HbA1c呈正相关(r=0.227,P<0.05;r=0.201,P<0.05;r=0.199,P<0.05);与2hIns呈负相关(r=-0.105,P<0.05)。结论二甲双胍格列吡嗪复方制剂在有效控制血糖的同时,还能降低VF水平并改善胰岛β细胞功能。VF水平的变化与血糖及胰岛素水平相关,可能在T2DM发生发展及临床治疗中发挥作用。
Objective To observe the effects of metformin combined with glipizide (group A) and monotherapy with metformin (group B) or glipizide (group C) on serum visfatin (VF) and pancreatic β-cell function in T2DM patients. Methods The levels of FPG, FIns, 2hPG, 2hIns, HbA1c, HOMA-IR, HOMA-β and VF were measured before and after treatment. Results After treatment, the levels of serum VF in A and C groups decreased (P <0.01) and HOMA-β in A group increased (P <0.01). Pearson correlation analysis showed that VF level was positively correlated with FPG, 2hPG and HbA1c (r = 0.227, P <0.05; r = 0.201, P <0.05; r = 0.199, P <0.05) and negative correlation with 2hIns (r = -0.105, P <0.05). Conclusions Metformin glipizide compound can effectively reduce the level of VF and improve the function of islet β cells while controlling blood glucose effectively. Changes in the level of VF and blood glucose and insulin levels, may play a role in the development of T2DM and clinical treatment.